Treatment

Risks of active surveillance for men with intermediate-risk prostate cancers

Men diagnosed with slow-growing prostate tumors that likely won’t be harmful during their lifetimes can often avoid immediate treatment. Instead, they can have their tumor monitored using a strategy called active surveillance. With this approach, doctors perform periodic checks for tumor progression and start treatment only if the cancer begins to metastasize, or spread. Active […]

Read more »

Promising results for a targeted drug in advanced prostate cancer

It’s well known that defective BRCA genes can increase a woman’s chances of developing breast, ovarian, and other cancers. But these same gene changes can also increase a man’s risk of dying from prostate cancer. Now, a new study published in The New England Journal of Medicine has shown that men with prostate cancer who […]

Read more »

Hormone therapy plus chemotherapy may boost survival in men with advanced prostate cancer

Combining a chemotherapy drug called docetaxel with hormone therapy (androgen-deprivation therapy) to treat advanced prostate cancer appears to work better than starting with hormone therapy and adding docetaxel later.

Read more »

Researchers identify possible cause of castration-resistant prostate cancer

New research has has identified an enzyme that may be the escape hatch that advanced prostate cancer uses to evade hormone therapy. If the findings hold up, the enzyme might be a prime target for a drug that would treat castration-resistant prostate cancer.

Read more »

Technology and decision-making: A patient’s story

How endorectal MRI helped one couple choose the “best” treatment for prostate cancer.

Read more »

What if I have prostate cancer and lymphoma?

There’s no one correct course of action. In general, experts recommend first treating whichever condition is worse.

Read more »

Anxiety drives some treatment decisions

Anxiety, not clinical symptoms and disease progression, may sway patients toward treatment.

Read more »

Outcomes research in prostate disease

When it comes to prostate cancer and other prostate diseases, how accurate are the statistics we hear? Can patients rely on reported figures to determine their risk of suffering complications such as incontinence and impotence? Why do data vary from one organization to another? Three experts discuss these questions and the growing field of outcomes research.

Read more »

Early-stage prostate cancer: Treat or wait?

When it comes to early-stage prostate cancer, there is no evidence that one treatment is better than another or that any treatment at all actually prolongs life. If you are diagnosed with early-stage prostate cancer, you’ll want to consider factors such as your values, your quality of life, and the potential side effects of various treatments before making a decision.

Read more »